Rigel Pharmaceuticals (RIGL) Operating Margin (2010 - 2026)

Rigel Pharmaceuticals' Operating Margin history runs 16 years deep, the most recent figure standing at 20.21% for Q1 2026.

• In Q1 2026, Operating Margin fell 374.0% year-over-year to 20.21%; the TTM figure through Mar 2026 stood at 41.56% (up 1993.0% YoY), while the FY2025 annual figure was 42.63%, up 2914.0% from the prior year.
• Operating Margin for Q1 2026 stood at 20.21%, down from 33.19% in the prior quarter.
• The five-year high for Operating Margin was 60.09% in Q2 2025, with the low at 156.92% in Q1 2022.
• The 5-year median for Operating Margin is 4.05% (2022), against an average of 8.64%.
• Peak annual rise in Operating Margin reached 10900 bps in 2022, while the deepest fall reached 20846 bps in 2022.
• Rigel Pharmaceuticals' Operating Margin stood at 4.05% in 2022, then jumped by 35 bps to 5.49% in 2023, then jumped by 426 bps to 28.92% in 2024, then gained by 15 bps to 33.19% in 2025, then slumped by 39 bps to 20.21% in 2026.
• Business Quant data shows RIGL's Operating Margin at 20.21% in Q1 2026, 33.19% in Q4 2025, and 40.91% in Q3 2025.